Chattem
This article was originally published in The Tan Sheet
Executive Summary
Chattanooga, Tenn.-based OTC and supplement maker's sales of $73.3 mil. for the third quarter ended Aug. 31 mark a 6.9% decline from the year-ago period. Sales in the Sunsource supplement line fell 35% and Gold Bond sales dipped roughly 14%, the company reports. Ban antiperspirant/deodorant revenues fell as well; Chattem announced it had sold the line to Andrew Jergens in August (1"The Tan Sheet" Aug. 28, p. 3). Chattem will launch Icy Hot pain relieving patch and Dexatrim Natural ephedrine-free in early 2001
You may also be interested in...
Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.
Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.
Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.